Walter Ageno1, Maria Cristina Vedovati2, Ander Cohen3, Menno Huisman4, Rupert Bauersachs5, Gualberto Gussoni6, Cecilia Becattini2, Giancarlo Agnelli2. 1. Department of Clinical Medicine, University of Insubria, Varese, Italy. 2. Internal, Vascular and Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy. 3. Department of Haematology, St. Thomas' Hospital, King's College, London, United Kingdom. 4. Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands. 5. Klinikum Darmstadt GmbH, Darmstadt, Germany. 6. Clinical Research Department, FADOI Foundation, Milan, Italy.
Abstract
BACKGROUND: Direct oral anticoagulants are recommended for the treatment of cancer-associated thrombosis (CAT) as an alternative to low-molecular-weight heparin (LMWH), but an increased bleeding risk in patients with gastrointestinal cancer was reported. The Caravaggio study compared apixaban and dalteparin for the treatment of patients with CAT. Here we describe sites of bleeding, associated cancer sites, clinical presentation, and course of major bleeding in patients included in the Caravaggio study. METHODS: The Caravaggio study was a multinational, randomized, open-label, noninferiority study. Bleeding events and the severity of major bleedings were adjudicated by a committee unaware of treatment allocation using predefined criteria; for the purpose of this analysis, data were analyzed in the safety population. RESULTS: Major bleeding occurred in 22 of 576 patients on apixaban (3.8%) and in 23 of 579 patients on dalteparin (4.0%). The sites of major bleeding and their distribution according to the type of cancer were similar between the two treatment groups. Major bleeding occurred in nine patients with gastrointestinal cancer in each treatment group. The clinical presentation of major bleeding was severe or fatal in 6 patients on apixaban and in 5 patients on dalteparin, while the clinical course was severe in 5 patients on apixaban and in 7 patients on dalteparin. CONCLUSION: Apixaban is a safe alternative to LMWH for the treatment in patients with CAT. No excess in gastrointestinal bleeding was observed in patients who received apixaban, including those with gastrointestinal cancer. Thieme. All rights reserved.
BACKGROUND: Direct oral anticoagulants are recommended for the treatment of cancer-associated thrombosis (CAT) as an alternative to low-molecular-weight heparin (LMWH), but an increased bleeding risk in patients with gastrointestinal cancer was reported. The Caravaggio study compared apixaban and dalteparin for the treatment of patients with CAT. Here we describe sites of bleeding, associated cancer sites, clinical presentation, and course of major bleeding in patients included in the Caravaggio study. METHODS: The Caravaggio study was a multinational, randomized, open-label, noninferiority study. Bleeding events and the severity of major bleedings were adjudicated by a committee unaware of treatment allocation using predefined criteria; for the purpose of this analysis, data were analyzed in the safety population. RESULTS: Major bleeding occurred in 22 of 576 patients on apixaban (3.8%) and in 23 of 579 patients on dalteparin (4.0%). The sites of major bleeding and their distribution according to the type of cancer were similar between the two treatment groups. Major bleeding occurred in nine patients with gastrointestinal cancer in each treatment group. The clinical presentation of major bleeding was severe or fatal in 6 patients on apixaban and in 5 patients on dalteparin, while the clinical course was severe in 5 patients on apixaban and in 7 patients on dalteparin. CONCLUSION: Apixaban is a safe alternative to LMWH for the treatment in patients with CAT. No excess in gastrointestinal bleeding was observed in patients who received apixaban, including those with gastrointestinal cancer. Thieme. All rights reserved.
Authors: Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Irene Terrenato; Francesca Sperati; Maddalena Barba; Victor Ed Yosuico; Holger Schünemann; Elie A Akl Journal: Cochrane Database Syst Rev Date: 2018-06-19
Authors: Rodrigo Abensur Athanazio; José Manuel Ceresetto; Luis Javier Marfil Rivera; Gabriela Cesarman-Maus; Kenny Galvez; Marcos Arêas Marques; Aldo Hugo Tabares; Carlos Alberto Ortiz Santacruz; Fernando Costa Santini; Luis Corrales; Alexander T Cohen Journal: Clin Appl Thromb Hemost Date: 2022 Jan-Dec Impact factor: 2.389
Authors: Marc Carrier; Normand Blais; Mark Crowther; Petr Kavan; Grégoire Le Gal; Otto Moodley; Sudeep Shivakumar; Deepa Suryanarayan; Vicky Tagalakis; Cynthia Wu; Agnes Y Y Lee Journal: Curr Oncol Date: 2021-12-18 Impact factor: 3.677